CCND1
Aliases:
This biomarker is also known as:- PRAD1
- U21B31
- B-cell lymphoma 1 protein
- cyclin D1
- G1/S-specific cyclin-D1
- BCL1
- PRAD1 oncogene
- BCL-1 oncogene
- BCL-1
- cyclin D1 (PRAD1: parathyroid adenomatosis 1)
- D11S287E
- B-cell CLL/lymphoma 1
- CCND1
Description…
CCND1 is a member of the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. CCND1 forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition.
Datasets
There are no datasets associated with this biomarker.
Attributes
| QA State: | Curated |
|---|---|
| Type: | Glycomic |
| HGNC Name: | CCND1 |
The following organs have data associated with this biomarker…
Attributes
| Phase: | 2 |
|---|---|
| QA State: | Under Review |
Organ-specific information for this biomarker is currently being annotated or is "under review".
Logging in may give you privileges to view additional information.
Contact the
Informatics Center
if you believe you should have access to this biomarker.
Attributes
| Phase: | 1 |
|---|---|
| QA State: | Under Review |
Organ-specific information for this biomarker is currently being annotated or is "under review".
Logging in may give you privileges to view additional information.
Contact the
Informatics Center
if you believe you should have access to this biomarker.
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
- Multianalyte tests for the early detection of cancer: speedbumps and barriers.
- Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.